National and international guidelines for the management of cardiovascular disease
| Organization | Recommendations |
|---|---|
| Canadian Task Force on Preventive Health Care98 | Recommend measuring height and weight and calculating BMI at appropriate primary care visits. |
| American College of Cardiology/American Heart Association Hypertension guideline67 | Lowered the definition of hypertension to 130/80 mm Hg. Target blood pressure for all groups is now < 130/80 mm Hg. |
| European Society of Hypertension/European Society of Cardiology67 | Base diagnosis of hypertension on out-of-office BP measures ambulatory BPM and home BPM if possible, or repeated office measures. Treatment threshold for very high CV risk now 130/85 mm Hg. BP treatment recommended for BP 140/90 mm Hg and higher in low-risk patients if no response to lifestyle intervention. Target BP < 140/90 mm Hg in all patients, < 120 mm Hg systolic if younger than 65 years, target systolic 130–139 mm Hg if 65 years or older.102 |
| American Diabetes Association and European Association of the Study of Diabetes99 | Recommend in addition to metformin, adding the newer antihyperglycemic agents, including DPP4 inhibitor, SGLT2 inhibitor and GLP-1 RA, and all groups recommend an A1c < 7.0 for most patients. |
| American College of Cardiology/American Heart Association Lipid guideline100 | Did not recommend a specific target but did advocate more intensive therapy or combination for those who did achieve a good response to statins (i.e., > 50% reduction). |
| European Society of Cardiology101 | Treat-to-target approach for lipid management, targeting an LDL-C < 1.8 mmol/L for very high-risk patients. |
Note: A1C = glycosylated hemoglobin, BMI = body mass index, BP = blood pressure, BPM = blood pressure monitoring, CV = cardiovascular, DPP4 = dipeptidyl peptidase-4, GLP-1 RA = glucagon-like peptide-1 receptor agonists, LDL-C = low-density liproprotein cholesterol, SGLT2 = sodium–glucose cotransporter 2.